Abstract
Apixaban, an oral anticoagulant, is frequently used in the prevention of stroke or systemic embolic events in patients with non-valvular atrial fibrillation. Apixaban, an active factor Xa inhibitor, may prolong partial thromboplastin time (PTT) and prothrombin time (PTZ) values. As with all anticoagulants, the use of Apixaban increases the risk of bleeding. Bleeding to the psoas muscle is a rare but serious complication. In this case report, we aimed to present acute renal failure due to spontaneous psoas muscle bleeding due to the use of Apixaban.
References
- Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619870249. doi: 10.1177/1076029619870249.
- Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011; 31:478–92.
- Granger CB, Alexander JH, McMurray JJ, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992 DOI: 10.1056/NEJMoa1107
- Wada Y, Yanagihara C, Nishimura Y. Bilateral iliopsoas hematomas complicating anticoagulant therapy. Intern Med 2005; 44:641–3. 10.2169/internalmedicine.44.641
- Zago G, Appel-da-Silva MC, Danzmann LC. Iliopsoas muscle hematoma during treatment with warfarin. Arq Bras Cardiol 2010; 94:1-3
Abstract
Oral bir antikoagülan olan Apiksaban valvüler olmayan atrial fibrilasyonlu hastalarda inme veya sistemik embolik olayların önlenmesinde sıkça kullanılmaktadır. Aktif bir faktör Xa inhibitörü olan Apiksaban parsiyel tromboplastin zamanı (PTT), protrombin zamanı(PTZ) değerlerini uzatabilmektedir. Tüm antikoagülanlarda olduğu gibi Apiksaban kullanımı kanama riskini arttırır. Psoas kasına kanama nadir görülen fakat ciddi bir komplikasyondur. Bu olgu sunumunda Apiksaban’ın kullanımı sonucu spontan gelişen psoas kası kanamasına bağlı gelişen akut böbrek yetmezliğini sunmayı amaçladık.
References
- Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619870249. doi: 10.1177/1076029619870249.
- Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis 2011; 31:478–92.
- Granger CB, Alexander JH, McMurray JJ, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992 DOI: 10.1056/NEJMoa1107
- Wada Y, Yanagihara C, Nishimura Y. Bilateral iliopsoas hematomas complicating anticoagulant therapy. Intern Med 2005; 44:641–3. 10.2169/internalmedicine.44.641
- Zago G, Appel-da-Silva MC, Danzmann LC. Iliopsoas muscle hematoma during treatment with warfarin. Arq Bras Cardiol 2010; 94:1-3
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Case Report |
| Authors | |
| Publication Date | December 15, 2019 |
| Submission Date | July 2, 2019 |
| Acceptance Date | September 10, 2019 |
| Published in Issue | Year 2019 Volume: 10 Issue: 38 |
